Voltage-gated LTCCs (L-type Ca 2+ channels) are established drug targets for the treatment of cardiovascular diseases. LTCCs are also expressed outside the cardiovascular system. In the brain, LTCCs control synaptic plasticity in neurons, and DHP (dihydropyridine) LTCC blockers such as nifedipine modulate brain function (such as fear memory extinction and depression-like behaviour). Voltage-sensitive Ca 2+ channels Ca v 1.2
Voltage-gated LTCCs (L-type Ca 2+ channels)
VGCCs (voltage-gated Ca 2+ channels) are key signalling elements allowing changes in membrane potential to control a large number of Ca 2+ -dependent responses in electrically excitable cells. These responses include muscle contraction, hormone and neurotransmitter release, neuronal plasticity and sensory cell signalling. To fit the kinetics and amplitude of voltage-gated Ca 2+ influx to the needs of individual cells, ten different pore-forming α 1 subunit isoforms exist that belong to three subfamilies (Ca v 1, Ca v 2 and Ca v 3) [1] . Channel function is fine-tuned by accessory subunits (α 2 -δ, β and γ ), alternative splicing and associated regulatory proteins, and it is dynamically regulated by receptor-dependent signalling pathways [1] . In addition, channels can sense intracellular Ca 2+ levels, thus establishing activity-dependent feedback mechanisms, like Ca 2+ -dependent inactivation or Ca 2+ -dependent facilitation [2] .
LTCCs are formed by the Ca v 1 family, which comprises isoforms Ca v 1.1, Ca v 1.2, Ca v 1.3 and Ca v 1.4 [1] . These can be distinguished from the other VGCC types by their high sensitivity to organic Ca 2+ channel blockers and activators, such as DHPs (dihydropyridines). Ca 2+ channel blockers are widely used for the treatment of cardiovascular diseases due to their cardiodepressant and vasodilatory actions. Their preferential action in the cardiovascular system is unexpected, considering the expression of LTCCs in a variety of electrically excitable cells outside the cardiovascular system. Whereas Ca v 1.1 and Ca v 1.4 expressions are restricted to skeletal muscle and retinal neurons respectively, the rest of the family displays a broad expression profile [1] : Ca v 1.2 and/or Ca v 1.3 are not only expressed in the cardiovascular system but also in different smooth-muscle cells, neurons, neuroendocrine cells (including the adrenal medulla and pancreatic β-cells), sensory cells (such as retinal neurons and cochlear hair cells) and, possibly, even immune cells [3] . In many of these tissues, Ca v 1.2 and Ca v 1.3 are expressed even together within the same single cell. This raises two important questions: do Ca v 1.2 and Ca v 1.3 channels serve different cellular functions? If so, could their isoformselective modulation be exploited to also treat other than cardiovascular diseases? Based on the important modulatory role of LTCCs in neurons (see below), it would be interesting to know which pharmacological effects result from the selective block of either Ca v 1.2 or Ca v 1.3 channels in the CNS (central nervous system). Notably, in earlier in vivo studies, high doses of DHPs (such as nifedipine) caused a variety of CNS effects (see below), but it remained unclear whether these effects were mediated by LTCCs or by non-specific blocking of other targets.
A big obstacle in addressing this question is the absence of isoform-selective LTCC modulators. When co-expressed with accessory β and α 2 -δ subunits in HEK-293 cells (human embryonic kidney cells), Ca v 1.2 and Ca v 1.3 channel complexes show very similar subnanomolar dissociation constants for the highly selective LTCC blocker (+)- [4, 5] . This is in excellent agreement with the fact that all amino acid residues known to participate in the formation of the DHP-binding pocket are conserved between these two α 1 subunits [6] . However, DHPs block LTCCs in a voltage-dependent manner, which is reflected by their preferred binding to the inactivated channel state [7] . This voltage-dependence differs for Ca v 1.2 and Ca v 1.3 and therefore Ca v 1.2 channels are blocked with approx. 10-fold lower IC 50 values at negative resting membrane potentials in electrophysiological studies [5, 8] . These experiments were carried out using relatively long depolarizing pulses (up to 50 ms) [5, 8] . However, DHPs block both channels more slowly and with higher IC 50 values upon stimulation by high frequency, action-potential-like waveforms, which are supposed to mimic neuronal firing [9] . These observations perfectly explain the preferential inhibition of cardiovascular Ca v 1.2 channels (the major isoform in this system, see below) by DHPs in vivo and can also account for the fact that modulation of CNS function requires higher doses. However, these findings also imply that currently available LTCC blockers are unsuitable pharmacological tools for dissecting the distinct physiological roles of Ca v 1.2 and Ca v 1.3.
Dissection of LTCC function in different tissues by generating suitable mouse models
We have generated two mouse models to dissect the physiological role and pharmacotherapeutic potential of Ca v 1.2 and Ca v 1.3 LTCCs (Figure 1 −/− mice showed two interesting phenotypes [10] : they were deaf, due to almost complete absence of L-type currents in cochlear hair cells, and they exhibited a SAN (sinoatrial node) dysfunction with bradycardia and arrhythmia [10, 12] . The Ca v 1.3-mediated Ca 2+ current components account for most of the voltage-gated Ca 2+ current in cochlear inner and outer hair cells [10, 13, 14] and in SAN cells [12] and activate at much lower voltages than Ca v 1.2 currents. Subsequent research from our and other groups [5, 8, 15, 16] −/− mice, the smooth-muscle relaxant and negative inotropic actions of DHPs (such as isradipine) were completely absent [4] . In contrast, verapamil block still occurred, as expected from the fact that the mutation does not decrease affinity for verapamil analogues [17] . This suggested that Ca 2+ influx through Ca v 1.2 channels controls smooth-muscle and cardiac contractility without detectable contribution of Ca v 1.3. In telemetric recordings, isradipine lowered heart rate by suppressing intrinsic SAN activity in WT as well as in Ca v 1.2DHP
−/− mice [4] , thus confirming the key role of Ca v 1.3 channels for normal SAN function.
This animal model also allowed us to address the controversial issue concerning the contribution of Ca v 1.3 to pancreatic β-cell Ca 2+ currents and insulin secretion. Three different mouse models as well as biochemical data have provided evidence both for a role of Ca v 1.3 in β-cells [18, 19] as well as against it [20, 21] −/− mice [4] . Furthermore, glucose-dependent insulin secretion from isolated islets was also no longer DHP-sensitive in Ca v 1.2DHP −/− mice. This supports the assumption that Ca v 1.3 does not contribute to I Ca and insulin secretion to a significant extent. All these findings are important, because they predict that selective Ca v 1.3 blockers can exert bradycardic actions without affecting vascular resistance, cardiac inotropy and pancreatic β-cell function. Such drugs could represent specific bradycardic agents to prevent angina pectoris by lowering cardiac oxygen consumption during exercise, and they could also counteract tachycardia in patients with chronic heart failure. An important modulatory role for LTCCs in brain function can be inferred from a number of observations. Together with Ca 2+ influx through NMDA (N-methyl-D-aspartate) receptors, Ca 2+ entry through LTCCs serves as a privileged signal for transmitting information about synaptic activation to the transcriptional machinery of the cell's nucleus (for a review, see [22] ). Activity-dependent nuclear signalling via LTCCs involves different signalling pathways, including activation of CREB, the Ras/MAPK (mitogen-activated protein kinase) pathway, and NFAT (nuclear factor of activated T-cells) translocation to the nucleus [22] . CREB serves as a critical signal integrator, which is responsive to a variety of environmental and pharmacological stimuli in a brain region-specific manner, and responsible for key CNS functions that involve learning and memory, depression-like and antidepressant-like effects and behavioural responses to drugs of abuse [22, 23] . CREB expression is under the tight control of LTCCs, and LTCC blockers inhibit CREB activation in cultured neurons [22] . Therefore DHP effects on the CNS, such as antidepressant-like effects previously described for DHP LTCC blockers in rodents and humans [4] , could be mediated through modulation of CREB signalling. [27] LTCCs were found to underlie this phenomenon and must therefore also be key players in mediating hippocampusdependent forms of memory [26] .
Anomalous LTCCs
Strong synaptic input can trigger plasticity even at the level of individual Ca 2+ channels. It has previously been shown, that strong depolarizing prepulses can induce an unusual ('anomalous') voltage-dependent gating behaviour of LTCCs studied by single-channel analysis in cerebellar granule cells [28] , hippocampal pyramidal neurons [29] and spinal motoneurons [30] .
Unlike typical 'cardiac-like' LTCCs, this anomalous gating behaviour was characterized by rare, short openings of very low open probability during (even strong) depolarizations, followed by long re-openings with high open probability at negative voltages after repolarization. This gating appears highly suitable for generating a surge of Ca 2+ influx following strong neuronal activity. Preliminary studies with Ca v 1.2DHP −/− mouse cerebellar granule cells indicate that Ca v 1.2 LTCCs contribute to the formation of these channels [31] . Note that Ca 2+ influx through LTCCs induces slow after-hyperpolarizations by activating Ca 2+ -dependent K + channels [32, 33] . Anomalous (and thus most likely Ca v 1.2) channels may therefore serve as important activators 
Embryo
Global gene knockout leads to intrauterine death before 14.5 days post coitum due to cardiac dysfunction [54] Gastrointestinal smooth muscle Smooth-muscle-specific conditional inactivation of Ca v 1.2 channels results in reduced faeces excretion, absence [55] of rhythmic contractions in small and large intestinal muscles and signs of paralytic ileus; extracellular field stimulation evoked smaller contractions in jejunum muscles
Vascular smooth muscle
Smooth-muscle-specific conditional inactivation of Ca v 1.2 channels results in reduced mean arterial blood [56] pressure in awake, freely moving animals; phenylephrine-and angiotensin-2-induced increases were blunted; depolarization-induced contraction was abolished in tibialis arteries and development of myogenic tone in response to intravascular pressure (Bayliss effect) was absent; 50% of the PE-induced resistance was found to be due to Ca 2+ influx through Ca v 1.2 channels Brain Selective loss of protein synthesis-dependent NMDA-receptor-independent Schaffer collateral/CA1 late-phase [26] LTP; severe impairment of hippocampus-dependent spatial memory; decreased activation of the MAPK pathway and reduced CRE-dependent transcription in CA1 pyramidal neurons of this 'brake' to limit Ca 2+ entry after strong synaptic activity. During pulse procedures that simulate postsynaptic depolarization in response to a burst of presynaptic action potentials (which would in turn elicit NMDA receptorindependent LTP; see above), anomalous channels in hippocampal pyramidal neurons were found to provide more Ca 2+ influx than 'cardiac-like' LTCCs. Therefore anomalous gating could significantly contribute to LTCC-mediated LTP [29] .
Ca v 1.3 channels can conduct low-voltageactivated L-type Ca 2+ currents that shape neuronal firing behaviour Affecting after-hyperpolarization is not the only way for LTCCs to modulate neuronal firing patterns. LTCCs affect neuronal resting potential (e.g. in hippocampal CA1 neurons; [34] ) and stabilize plateau potentials in many neurons, such as in motoneurons [35, 36] , deep dorsal horn neurons [37] and medium spiny neurons in the striatum [38] and nucleus accumbens [39] . Direct evidence that such upstate potentials and the ensuing spontaneous firing activity are mediated by Ca v 1.3 channels has recently been obtained in striatal spiny neurons of Ca v 1.3 −/− mice, where this activity was completely absent [38] . The preferential contribution of Ca v 1.3 rather than Ca v 1.2 channels to upstate potentials can be explained by their lower activation threshold and the lower tendency to inactivate during maintained depolarizations [5] .
Taken together, these results reveal a key role of Ca v 1.2 and Ca v 1.3 channels in neuronal activity and plasticity, and prompt questions about the physiological role of these channels for neuronal function and animal behaviour in vivo.
Role of Ca v 1.2 and Ca v 1.3 LTCCs for in vivo brain function and mouse behaviour
One straightforward approach to address this question is to systemically apply DHP Ca 2+ channel blockers and activators to laboratory animals and test for pharmacological effects on brain function.
Effects of DHP LTCC blockers on CNS
A number of different pharmacological effects have been described after application of high doses of DHP LTCC blockers to rodents. These include amelioration of age-related working memory deficits [40] , anxiolytic and antidepressantlike actions [4, 41] , inhibition of fear memory extinction [42] , anticonvulsive effects [43] , and effects on drug-taking behaviour [23] . However, the interpretation of these results has always been challenged by the assumption that high doses of DHPs may not be specific to LTCCs and may interfere with other signalling pathways as well (e.g. nicotinic acetylcholine receptors, [44] 
Effects of DHP LTCC activators on CNS
Systemic application of LTCC activators, such as BayK 8644, results in a severe dystonic neurobehavioural syndrome in rodents, which is characterized by reduced ambulation, hypokinetic and bradykinetic motor dysfunction, abnormal postures and, at increased doses, self-biting behaviour [4, 45] . Although this finding emphasizes the role of LTCCs in the development of dystonic episodes, it also prevents detailed studies of LTCC activation on other aspects of mouse behaviour. In Ca v 1.2DHP −/− mice, even high doses of BayK 8644 did not lead to changes in motor function or spontaneous motility, demonstrating that activation of Ca v 1.2 channels solely accounts for the BayK 8644-induced dystonic neurobehavioural syndrome [4] . In addition, this observation enabled us to experimentally address the following questions in these mice: (i) does selective activation of Ca −/− mice completely prevented the stimulation of glutamate and 5-HT efflux, whereas stimulated noradrenaline efflux was unchanged and stimulated dopamine efflux was only partially reduced. In the ventral striatum, BayK 8644-induced noradrenaline efflux must therefore be mediated by Ca v 1.3, while glutamate and 5-HT efflux require Ca v 1.2. Dopamine efflux stimulation is mediated by both LTCC isoforms. These experiments could not reveal whether locally applied BayK 8644 enhances neurotransmitter efflux either directly by activation of presynaptic LTCCs or indirectly by affecting striatal neuronal networks that control neurotransmitter efflux from these afferents. However, they demonstrated that the selective activation of Ca v 1.3 is sufficient to stimulate extraneuronal dopamine and noradrenaline activity in this particular brain area. This finding prompted us to investigate which neuronal circuits are activated upon selective Ca v 1.3 activation, by using Fos expression as a marker for neuronal activation [4] . Vehicle injection elicited only low numbers of Fos-positive cells, which were similar in WT and mutants. In WT mice, BayK 8644 (2 mg/kg intraperitoneal) evoked widespread Fos expression in most of the 65 brain areas investigated [4, 46] , which is in accordance with the severe dystonic syndrome described above. In contrast, BayK 8644-induced Fos expression was considerably attenuated in most brain regions of Ca v 1.2DHP −/− mice and even in regions with a very high density of Fos-positive cells in WT. Notably, significant BayK 8644-induced Fos expression in Ca v 1.2DHP −/− mice was detectable only in a small subset of brain regions, particularly in the central amygdala, the BNST (bed nucleus of the stria terminalis), the PVN (paraventricular hypothalamic nucleus), the lateral preoptic area, in the locus coeruleus, the lateral parabrachial nucleus, the central nucleus of the inferior colliculus, and in the nucleus of the solitary tract [4, 46] . This indicates that selective stimulation of Ca v 1.3 channels restricts (apparently non-toxic) neuronal activation to a specific set of mainly limbic, hypothalamic and brainstem areas, which are associated with brain functions concerning integration of emotion-related behaviour.
Some of the regions activated by BayK 8644 in Ca v 1.2DHP −/− mice, such as the PVN, the BNST, the ventral striatum or the amygdala, are part of anatomical circuits implicated in the processing of depression-related behaviour [47] . As mentioned above, we could show that the antidepressant-like effects of DHP LTCC blockers are due to inhibition of Ca v 1.2 channels. The results from the BayK 8644 experiments supported the idea that activation of Ca v 1.3 might also affect emotional behaviour in mice. We could indeed demonstrate that BayK 8644 administration results in a depression-like behaviour in Ca v 1.2DHP
−/− mice in the FST. BayK 8644 neither affected motor function in the rotarod treadmill test (see above), nor did it alter spontaneous motor activity in the open field test. This emphasized the specificity of the BayK 8644 response in the FST. Our results suggest that both Ca v 1.2 and Ca v 1.3 channels control emotional behaviour in mice. This is further supported by preliminary experiments from our group, which indicate that Ca v 1.3 deficiency is associated with a pronounced antidepressant and anxiolytic-like behaviour [48] .
Conclusions
Published and ongoing experiments with mouse models suitable to dissect Ca v 1.2 and Ca v 1.3 function in the brain and in other tissues reveal an interesting pharmacological profile for Ca v 1.3 channels. It appears that the selective inhibition of these channels would result in antidepressant and anxiolytic effects, without affecting hippocampal LTP and hippocampus-dependent forms of memory, fear memory (A. Hetzenauer, P. Busquet and N. Singewald, unpublished work), peripheral vascular resistance, cardiac inotropy, other types of smooth muscles (e.g. gastrointestinal smooth muscle) or insulin secretion; these effects, at least in mice, are all mediated by Ca v 1.2 and not by Ca v 1.3 (Table 1) . Like clinically used Ca 2+ channel blockers, Ca v 1.3-selective blockers may have bradycardic actions, which, in the case of anxiety disorders, could be useful therapeutically. A potential side effect that can be predicted from our studies is an elevation of the hearing threshold, which will ultimately depend on the ability of a drug to penetrate into the endolymphatic space. Taken together, dissection of the physiological role of different LTCC isoforms may provide a rational basis for the development of novel LTCC modulators and may extend the pharmacotherapeutic potential of these drugs beyond their established clinical use in cardiovascular disease.
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